Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247688 | 0.79 | POLB (0.64) | POLBNPC1RAB9AMEN1LMNA | |
| SCHEMBL1491115 | 0.79 | POLB (0.64) | POLBNPC1RAB9AMEN1LMNA | |
| SCHEMBL1491089 | 0.79 | POLB (0.64) | POLBNPC1RAB9AMEN1LMNA | |
| SCHEMBL1491136 | 0.78 | POLB (0.69) | POLBMEN1LMNANFKB1KMT2A | |
| SCHEMBL433371 | 0.78 | POLB (1.00) | POLBNPC1RAB9AMEN1LMNA | |
| SCHEMBL544859 | 0.77 | POLB (0.61) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4953428 | 0.76 | POLB (0.78) | POLBNPC1RAB9AMEN1GLA | |
| Hydrochloric Acid SCHEMBL18692736 | 0.76 | POLB (0.59) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL24185602 | 0.75 | NPBWR1 (0.40) | POLBNPC1RAB9AMEN1LMNA | |
| SCHEMBL15299343 | 0.75 | NPC1 (0.41) | POLBNPC1RAB9AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145822-A1 | SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN | FONDAZIONE TELETHON (IT) | 2023-05-11 | — | — | US | disclosed |
| EP-4126225-A1 | SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN | Istituto Nazionale di Fisica Nucleare (IT) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021191883-A1 | SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN | ISTITUTO NAZIONALE DI FISICA NUCLEARE (IT) | 2021-09-30 | — | — | WO | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| EP-1893597-B1 | AMPA RECEPTOR POTENTIATORS | LILLY CO ELI (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7393868-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1893597-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142441-A1 | AMPA receptor potentiators | ELI LILLY AND COMPANY | 2007-06-21 | — | — | US | disclosed |
| WO-2006132811-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2006-12-14 | — | — | WO | disclosed |
| US-6410533-B1 | THERAPY FOR BACTERIA INFECTIONS | GENZYME CORPORATION | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142441-A1 | AMPA receptor potentiators | GABRE, GRIN1, GRIK2 | POLB 2569/4885NPC1 1985/4885RAB9A 2816/4885 |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | POLB 4247/4885NPC1 383/4885RAB9A 2005/4885 |
| US-20230145822-A1 | SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN | PRNP, PPIE, PPIC | POLB 3700/4885NPC1 1154/4885RAB9A 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.